Nurse-led Decision Counseling on Hepatocellular Carcinoma Screening

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

178 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis worldwide. The asymptomatic of early-stage HCC may lead most patients diagnosed at advanced stages. This highlights the importance of HCC screening among high-risk populations to detect HCC at early stages and achieve better survival. Hepatitis B virus (HBV) infection is a major cause of HCC in China, but the utilization of HCC screening is suboptimal among patients with HBV infection.

Currently, there are no-theory based intervention, to our knowledge, has been reported to improve HCC screening decision-making and uptake among patients with HBV infection . Therefore, based on our previous systematic review, the current study has proposed a nurse-led decision counseling program to improve decision-making and uptake of HCC screening among patients with HBV infection in mainland China.

Participants in intervention group will receive nurse-led decision counseling. The intervention components include 40-minute education and tailored information regarding HCC screening. At the second week, decision support will be provided through 30-minute telephone call. At the third week, another telephone call (20 minutes) will be provided to help participants identify and address barriers to HCC screening.

Participants in control group will receive usual care. After the intervention and at 3-month follow-up, the study will collect data related to HCC screening uptake rates. Findings are paramount to promote informed choice in HCC screening and early HCC detection to improve survival outcomes among patients with HBV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

NCT00629421

Cirrhosis Hepatocellular Carcinoma

COMPLETED

Hepatocellular Cancer (HCC) Screening in Zhongshan City

NCT02501980

Liver Neoplasms

UNKNOWN

Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma

NCT05256459

Time

UNKNOWN

Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma

NCT00912847

Hepatitis B Virus

COMPLETED

RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System

NCT02312817

Carcinoma, Hepatocellular Liver Neoplasms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in the intervention group will receive the following three-week, three-session intervention. The details are as follows.

Education (20 min). At first week, education will be delivered through face-to-face for the following information: (1) HBV infection and increased HCC risk; (2) HCC screening recommendations regarding eligibility, available screening tests and recommended screening intervals; (3) pros/advantages of undergoing HCC screening; (4) cons/disadvantages or uncertainties of undergoing HCC screening; (5) implications of positive screening results; and (6) health costs. The education material will be present in a self-made manual, which will be explained and distributed to each participant.

Tailored psychosocial information (20 min). It will be conducted after education. The tailored messages will be developed to form a message library for each sub-scale of the preventive health model instrument with scoring ≤ 3 and \> 3. The contents will be based on HCC screening guidelines and recommendations. The nurse counsellor will select and explain tailored information based on individual's responses to the preventive health model instrument.

Values clarification exercises (30 min). At the second week, the decision counselor will work with participants through telephone-based way to go through values clarification exercises, in which participants will: (1) review the listed pros and cons decision factors of undergoing HCC screening one by one; (2) indicate the extent to which each pros and cons matters to them by giving stars; (3) add any other reasons for choosing or not choosing HCC screening and indicate their importance; and (4) indicate their decision preferences toward undergoing HCC screening, unsure, or not undergoing HCC screening.

Exploring and addressing implementation barriers (20 min). At the third week, the decision counselor will work with participants, through telephone-based ways, to explore possible barriers to undertake HCC screening; identify possible solutions or available resources to the identified barriers via brainstorming; and encourage implementation of the chosen solution to overcome the barriers and schedule for HCC screening.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nurse-led decision counseling group

Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Group Type EXPERIMENTAL

Nurse-led decision counseling

Intervention Type OTHER

Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Control group

Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.

Group Type OTHER

Usual care

Intervention Type OTHER

Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nurse-led decision counseling

Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Intervention Type OTHER

Usual care

Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with HBV infection (HBsAg positive), aged 18-65 years old
* have been recommended to have HCC screening, including liver cirrhosis, males over age 40, women over age 50, and family history of HCC
* can understand Chinese
* without an liver ultrasound or serum alpha-fetoprotein test in the previous six months at the time of inclusion

Exclusion Criteria

* have comorbid condition, including co-infection with hepatitis C, human immunodeficiency virus, and alcoholic liver disease
* have hepatocellular carcinoma diagnosis
* have undergone liver transplantation
* have encephalopathy
* not willing to participate

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No